VRTX — Vertex Pharmaceuticals Incorporated
$523.93-2.10%
Last close: · regular session
Last 60 sessions
VRTX closed at $523.93 (-2.10%) on Oct 23, 2026. Float: 252.9M shares. Latest SEC filing: S-8 POS on May 13, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for VRTX in the TickerWise workspace.
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 6,100
- Website: https://www.vrtx.com
Latest SEC filings for VRTX
Latest VRTX news
- Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change. Read article
- Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know Read article
- Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now? Read article
- Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts Read article
- Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders Read article
- Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know Read article
- Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know Read article
- Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.